What It’s Like to Participate in the BriaCell Bria-IMT™ Clinical Trial
Metastatic breast cancer is often an overwhelming diagnosis that may involve a wide range of symptoms that make the journey more challenging. Side effects from treatments can be equally difficult to manage. Adding in the emotional toll of finding out your breast cancer has spread can lead to loneliness and hopelessness.
But clinical trials bring a bit of light to a sometimes dark season of life. The possibilities of innovative treatments give you a path forward where you couldn’t see one previously. Phase 3 clinical trial of Bria-IMT™ (listed on ClinicalTrials.gov as NCT06072612) is one such clinical trial option that could treat your metastatic breast cancer in new ways.
Why This Trial Is Different
While Bria-IMT™ is a targeted immunotherapy option, it’s an innovative off-the-shelf treatment that ignites the immune system to target only the cancer cells.
Because of its successful outcomes during the Phase 2 study, Bria-IMT™ received Fast Track status by the FDA. This designation accelerates the development and review processes of promising treatments that could provide life-saving treatments.
A successful Phase 3 study, being conducted on metastatic breast cancer, could lead to Bria-IMT™ being fully approved. That means more patients will be able to have access to this innovative, targeted immunotherapy for treating cancer.
Through the trial, BriaCell aims to show a survival benefit that is greater than that of the existing standard of care therapy.
The Trial Experience: From Enrollment to Treatment
Starting a clinical trial for cancer treatment is taking a journey into the unknown. You are putting your faith in BriaCell, and we take that seriously.
The Phase 3 Bria-IMT™ trial is currently enrolling patients who qualify.
To participate in the clinical trial, you first must meet certain eligibility requirements, which include:
- Being 18 years old or older
- Advanced or metastatic breast cancer with no approved alternative therapies available
The Bria-IMT™ regimen takes place in 3-week cycles and is an ongoing treatment option. It involves a pre-treatment for 2 to 3 days before having the Bria-IMT cells injected. A few days later, patients receive interferon. Some patients also receive an infusion of a checkpoint inhibitor. Some patients will receive another treatment at the discretion of their oncologist.
Monitoring is ongoing throughout the treatment process. Initially, imaging scans take place every 6 weeks and then the scans occur every 8 weeks. Patients are also monitored for any adverse events that might be related to the treatment.
Focusing on the Human Element
The Bria-IMT™ trial is a highly collaborative research project involving numerous patients and top-tier institutions and investigators. The locations are listed in the ClinicalTrials.gov website (https://clinicaltrials.gov/study/NCT06072612).
The researchers and institutions are pivotal in this clinical trial, but it’s the patients who make the difference. By accessing these emerging treatment options, the patients are also seeing promising results. One patient in the Bria-IMT™ Phase 2 study experienced sustained, complete resolution of a temporal lobe brain metastasis. The patient also had a reduction in a tumor behind the eye.
With a strong safety profile, the Bria-IMT™ clinical trial brings hope to participants. To date, there have been no participants who have discontinued the trial due to treatment-related issues.
Bria-IMT™ Offers a Promising Option
BriaCell remains committed to developing novel treatments for cancer. That includes Bria-IMT™, which offers a promising approach based on the clinical trials. See if you qualify for the Bria-IMT™ trial. It could be the cancer treatment that changes your life and brings hope to the journey.